Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
Sotagliflozin
LEXICON PHARMACEUTICALS, INC.
Type 1 Diabetes Mellitus (T1DM)
1 trial -
Sotagliflozin
LEXICON PHARMACEUTICALS, INC.
Heart Failure
2 trials -
Sotagliflozin (SAR439954)
LEXICON PHARMACEUTICALS, INC.
Type 2 Diabetes Mellitus
4 trials -
Sotagliflozin Low Dose
LEXICON PHARMACEUTICALS, INC.
Type 1 Diabetes (T1D)
1 trial -
Sovateltide, Sovateltide matching placebo
Lacuna Pharma Pty Ltd
Acute cerebral ischemic stroke
1 trial -
Spesolimab, Placebo matching to Spesolimab
Boehringer Ingelheim
Hidradenitis Suppurativa (HS)
1 trial -
Spravato 28 mg nasal spray, solution, Midazolam-ratiopharm® 2 mg/ml orale Lösung, Oral placebo, Intranasal Placebo
Janssen-Cilag International N.V.
Major Depressive Disorder
1 trial -
St Thomas
Jazz Pharmaceuticals Ireland Limited
Coronary Artery Stenosis
1 trial -
Start antiplatelet monotherapy
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Intracerebral Hemorrhage
1 trial -
Statins
Arrowhead Pharmaceuticals Ireland Limited
Intracerebral Hemorrhage
1 trial -
Stimus (NNG-DEPO)
Biotech Pharmaceutical Co.,
Anemia
1 trial -
Suprefact Depot 9,45 mg implantat, Pamorelin 11,25 mg, poeder en oplosmiddel voor suspensie voor injectie, met verlengde afgifte., Pamorelin 22,5 mg, poeder en oplosmiddel voor suspensie voor injectie, met verlengde afgifte., Pamorelin 3,75 mg, poeder en oplosmiddel voor suspensie voor injectie, met verlengde afgifte., Eligard 45 mg poeder en oplosmiddel voor oplossing voor injectie, LEUPRORELIN ACETATE, CAMCEVI 42 mg prolonged-release suspension for injection, Gonapeptyl Depot 3,75 mg poeder en oplosmiddel
Disc Medicine
low-volume metastatic castration-sensitive prostate cancer
1 trial -
Suzetrigine
Vertex Pharmaceuticals (Australia) Pty.
Diabetic Peripheral Neuropathic Pain
3 trials -
Suzetrigine (SUZ)
Vertex Pharmaceuticals (Australia) Pty.
Acute Pain
1 trial -
Symbicort, 160 mikrogram/4,5 mikrogram/puff inhalationsspray, suspension, BFF (PT009), BD ( PT008), SALBUTAMOL, Placebo MDI and empty TBH devices (only for training purposes)
AstraZeneca AB
Inadequately Controlled Asthma
1 trial -
T89 Placebo; capsules contain brown coated dripping pills., Nitroglycerin Orifarm 0,5 mg tabletes lietošanai zem mēles
Lacuna Pharma Pty Ltd
Stable Angina Pectoris
1 trial -
TACROLIMUS, ALPN-303 solution for injection in pre-filled syringe, TACROLIMUS, TACROLIMUS, ALPN-303 solution for injection, Test IMP without active substance, ALPN-303 Solution for Injection in Pre-filled Pen
Vertex Pharmaceuticals (Australia) Pty.
Primary Membranous Nephropathy
1 trial -
TAGRISSO 80 mg film-coated tablets, TAGRISSO 40 mg film-coated tablets, PLACEBO
AstraZeneca AB
Stage IB-IIIA non-small cell lung carcinoma, with a centrally confirmed, common sensitising EGFR mutations (Ex19del and L858R either alone or in combination with other EGFR mutations), following complete tumour resection with or without adjuvant chemotherapy
1 trial -
TAGRISSO 80 mg film-coated tablets, TAGRISSO 40 mg film-coated tablets, PLACEBO
AstraZeneca AB
Histologically documented non-small cell lung cancer of predominantly non-squamous pathology who present with locally advanced, unresectable (Stage III) disease, whose tumor tissue has EGFR exon 19 deletions or exon 21 (L858R) substitution mutations, either alone or in combination with other EGFR mutations, as detected by cobas® EGFR Mutation Test v2 (Roche Diagnostics) and whose disease has not progressed following definitive platinum-based chemoradiation.
1 trial -
TAGRISSO 80 mg film-coated tablets, TAGRISSO 40 mg film-coated tablets, Placebo
AstraZeneca AB
Stage IA2-IA3 non-small cell lung carcinoma, with EGFR mutation type (Ex19del, L858R), following complete tumour resection.
1 trial -
TAGRISSO 80 mg film-coated tablets, TAGRISSO 40 mg film-coated tablets, placebo capsule G065, placebo capsule G040, JNJ-61186372, JNJ-73841937, JNJ-73841937-ZCY Placebo Oral Film-Coated Tablet
Janssen-Cilag International N.V.
EGFR-mutated locally advanced or metastatic Non Small Cell Lung Cancer
1 trial -
TAK-861, TAK-861 placebo (same excipients as TAK-861)
Takeda
Narcolepsy with Cataplexy (Narcolepsy Type 1)
1 trial -
TAK-861, TAK-861 placebo (same excipients as TAK-861), TAK-861
Takeda
Narcolepsy with Cataplexy (Narcolepsy Type 1)
1 trial -
TAK-861, TAK-861 placebo (same excipients as TAK-861), TAK-861
Takeda
Narcolepsy with Cataplexy (Narcolepsy Type 1)
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources